According to a recent report, a two-year-old Boston-based life firm called Orig3n, will begin making stem cells available to researchers to accelerate the drug development. They hope of doing this with $12.5 million which they have collected in recent funding.
Orig3n has been building a repository of people’s cells since earlier this year, transforming them into stem cells to test medicines and understand disease. Recent funding was led by Hatteras Venture Partners and Syno Capital, with participation from DEFTA Partners and existing investors Harris & Harris Group Inc, LapCorp, MGC Venture Partners, and KTB-KORUS Fund. 
Robin Smith, CEO of Orig3n said in a statement that they are developing some innovative science and business models that enable researchers to develop safer and more effective drugs and lay down the foundations for regenerative medicine treatments.
According to federal filings, the company had raised over $15.5 million in funding. This is an amount which comes up without even counting the most recent funding. That includes a $3 million round in February.
That's helped the company establish two services. LifeCapsule allows patients to donate their cells to be turned into stem cells for research. Patients can also store their cells, which can be used to create individual treatments for patients or select treatments that might work best on an individual, the company says on its website.
Orig3n also offers a service called LifeProfile, a genetic profiling service that gives users information on their genetic fitness and skin makeup, the website details.
Funding will support the newest service, coming in 2016, which will make cells in the repository available to researchers wanting to test their drugs on the cells to understand drug toxicity and drug efficacy.
“We are giving millions of people the channel to advance the future of medicine by contributing to a better understanding of disease and to remove the trial and error approach to medical treatment,” Smith said.
View Latest News: